PolyPid (PYPD)

Currency in USD
4.8400
+0.1100(+2.33%)
Closed·
4.7999-0.0401(-0.83%)
·

PYPD Earnings

Latest Release
Aug 12, 2026
EPS / Forecast
-0,35 / -0,40
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
2026/09--/-0,315--/0,000----Free Sign Up
2026/06-0,350/-0,4000,000/0,000+12,5%--Free Sign Up
2026/030,350/-0,3500,000/0,000+200%--Free Sign Up
2025/12-0,410/-0,3300,000/0,000-24,24%--Free Sign Up
2025/09-0,370/-0,3300,000/0,000-12,12%--Free Sign Up
2025/06-0,780/-0,570--/0,000-36,84%--Free Sign Up
2025/03-0,700/-0,920--/0,000+23,91%--Free Sign Up
2024/12-1,13/-0,9140,000/0,000-23,63%--Free Sign Up
2024/09-1,22/-1,000,000/0,000-22%--Free Sign Up
2024/06-1,25/-1,300,000/0,000+3,85%--Free Sign Up

All numbers in USD

PolyPid Earnings Call Summary for Q2/2026

  • PolyPid narrowed Q2 2026 loss to $7.8M ($0.35/share) from $10M ($0.78/share) YoY, beating estimates by 12.5%; shares fell 5.92% premarket to $4.45.
  • FDA accepted D-PLEX100 NDA with priority review, setting PDUFA goal date of Nov. 28, 2026; European Medicines Agency submission planned for Q3 2026.
  • Azurity Pharmaceuticals partnership secured $30M upfront with potential $290M+ in milestones; deal includes royalties and label-expansion funding.
  • Cash position of $6.6M at June 30 plus Azurity proceeds expected to fund operations into 2028; early 2027 launch targeted if FDA approval obtained.
  • Label expansion planned for cardiac surgery, orthopedic procedures, and breast reconstruction beyond initial abdominal surgery indication.
Last Updated: 2026/08/12, 15:26
Read Full Transcript

FAQ

What Is PolyPid's Earnings Per Share (TTM)?

The PolyPid EPS (TTM) is -1,7799.

When Is The Next PolyPid Earnings Date?

PolyPid will release its next earnings report on Nov 11, 2026.

What Is PolyPid’s Revenue Forecasts For Upcoming Quarters?

PolyPid’s revenue forecast is 0.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.